Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health www.cancer.gov
CCR - For Our Staff| Home |

Our Science – Schnermann Website

Martin J. Schnermann, Ph.D.

Portait Photo of Martin Schnermann
Chemical Biology Laboratory
Head, Organic Synthesis Section
Investigator
Center for Cancer Research
National Cancer Institute
Building 376, Room 225D
P.O. Box B
Frederick, MD 21702
Phone:  
301-228-4008
Fax:  
301-846-6033
E-Mail:  
schnermannmj@mail.nih.gov

Biography

Dr. Schnermann attended Colby College and graduated in 2002 with degrees in Chemistry (honors with Prof. Dasan Thamattoor) and Physics. After a year at Pfizer Research and Development (Groton, CT) as an associate in the medicinal chemistry division, he moved to the Scripps Research Institute. During his graduate studies, he performed research on the total synthesis and biological evaluation of anticancer natural products with Prof. Dale Boger and obtained a Ph.D. in 2008. He then completed an NIH-postdoctoral fellowship with Prof. Larry Overman at the University of California, Irvine. At Irvine, he developed light-mediated reactions to enable the synthesis of complex natural products. In addition, working with Prof. Christine Suetterlin, he pursued chemical biology and imaging studies of organelle specific probes. In 2012, Dr. Schnermann joined the NCI where his research focuses on the synthesis and development of new small-molecule imaging agents for cancer treatment and diagnosis.

Research

Near-IR Light-Cleavable Linkers for Targeted Drug Delivery
Light is used in a variety of cancer treatments ranging from well-established therapeutic techniques, such as PDT, to emerging areas such as fluorescence-guided surgery. Separately, the last decade has seen the clinical success of a number of antibody-drug conjugates. An enduring challenge is the development of precisely controlled linker strategies. To address this, we are developing light-cleavable linkers for targeted drug delivery. This approach would merge the unique potency of small molecule drugs with the high spatial control afforded by light release and molecular targeting. Central to our efforts is the development of release or uncaging reactions initiated by tissue penetrant, cytocompatible near-IR light. This is critical because existing uncaging chemistry uses UV or blue light, which is not suitable for many in vivo applications. To develop near-IR uncaging reactions, we use the intrinsic chemistry of near-IR fluorophores. These reactions were often first encountered in the context of mechanistic studies to determine the basis of fluorophore photochemical decomposition or photobleaching. Using the inherent reactivity of near-IR fluorophores, we are developing broadly useful tools for targeted drug delivery, with additional applications in a variety of contexts where near-IR uncaging would be beneficial.
Fluorophores for Cancer Imaging
The discovery and implementation of molecularly targeted optical imaging modalities for cancer diagnosis and treatment has progressed considerably. The development of bright, chemically stable, and easily synthesized fluorophores in the near-IR range is critical for clinical advances in this area. Despite a central role in modern biology techniques, the compounds employed in near-IR fluorescence have changed little in recent decades. The studies discussed above have provided a number of insights regarding the reactivity of common near-IR fluorophore scaffolds. For example, we have encountered compounds with improved chemical stability and reduced photobleaching rates. Using these insights, and molecular design principles and techniques borrowed from related fields (e.g. medicinal chemistry and modern organic synthesis), we seek to develop improved variants of these extensively used biological tools.

This page was last updated on 7/3/2014.